EU: Our prioritized markets for launch are the UK, Germany and Sweden. Commercialization of NeoNavia has begun and centers in Germany, UK and Sweden have started to evaluate the system in their own environment.
Outside the EU: The work to file for FDA approval in the US is ongoing and the US registration will pave the way for initiating an approval process in China.
The plan is to follow up with launches in both markets immediately after approved applications. In China, we have a stable and long-term owner in Boai NKY Medical Holdings Ltd, an established and respected player in the Chinese MedTech market.
Biopsy Marker. We are developing a technology for a biopsy marker optimized for ultrasound. The marker will be a valuable addition to the NeoNavia system and will facilitate further tissue sampling for patients undergoing treatment.
Skin biopsy instrument. We also run a development project in a separate company, Szafran Biopsy AB, together with dermatologist Rebecca Szafran. The company will further develop an improved punch biopsy instrument for more efficient sampling of skin changes. NeoDynamics supports the project with key competence.
increase in breast cancer diagnoses every year
breast biopsies are performed every year
is the size of the market in the breast cancer domain